S-1/A: Salarius Pharmaceuticals Announces Merger with Decoy Therapeutics, Aims for Novel Peptide Conjugate Therapies

Salarius Pharmaceuticals is set to merge with Decoy Therapeutics, focusing on developing innovative peptide conjugates for infectious diseases and oncology, contingent on a $6 million financing and Nasdaq listing.

Summary

• Salarius Pharmaceuticals is merging with Decoy Therapeutics to focus on peptide conjugate therapeutics.
• The merger is structured as a stock-for-stock transaction, with Decoy stockholders owning approximately 85.9% of Salarius after the merger, before accounting for the Qualified Financing.
• The merger is contingent on securing at least $6.0 million in financing and maintaining Salarius' Nasdaq listing.
• Decoy's IMP 3 ACT platform leverages machine learning and high-speed synthesis to develop peptide conjugates.
• The combined company will focus on infectious diseases and oncology, with plans to explore peptide-based proteolysis targeting chimeras (P-PROTACs) using Salarius' SP-3164 compound.
• Salarius' legacy stockholders would retain approximately 14.1% of Salarius on an as-converted-to-common basis, before taking into account the dilutive effects of the Qualified Financing.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the merger with Decoy Therapeutics and the focus on innovative peptide conjugate therapies are positive, the financial challenges, Nasdaq deficiency notice, and termination of a clinical trial raise concerns.

Positives

• The merger aims to create a leading biopharmaceutical company in the peptide conjugate therapeutics field.
• Decoy's IMP 3 ACT platform has the potential to change the economics of antiviral drug development.
• The combined company plans to integrate Salarius' SP-3164 to create peptide-based proteolysis targeting chimeras (P-PROTACs).
• Decoy's expertise in peptide conjugates complements Salarius' small molecule assets, potentially addressing a wider range of diseases and undruggable targets.

Negatives

• Salarius has received a deficiency notice from Nasdaq and may be delisted.
• Salarius terminated its Phase 1/2 clinical trial for Ewing sarcoma due to lack of funding.
• The merger is contingent on securing at least $6.0 million in financing, which may be dilutive to existing shareholders.
• Decoy's financial condition raises substantial doubt regarding its ability to continue as a going concern.
• Decoy has never generated revenue from product sales, and all of its product candidates are in the preclinical stage.

Risks

• The merger may be completed even if certain events occur that materially and adversely affect Salarius or Decoy.
• Stockholders of the combined company may not realize a benefit from the merger commensurate with the ownership dilution they will experience.
• The combined company will need to raise additional capital, which may cause dilution or restrict operations.
• The market price of Salarius common stock following the merger may decline.
• Decoy's financial condition raises substantial doubt regarding its ability to continue as a going concern.
• Decoy has never generated revenue from product sales and all of Decoy's product candidates are currently in the preclinical stage.

Future Outlook

The combined company expects to focus on developing innovative peptide conjugates as a major therapeutic drug modality, initially focusing on infectious diseases and oncology.

Industry Context

The announcement reflects a trend in the pharmaceutical industry towards mergers and acquisitions to expand pipelines and leverage complementary technologies, particularly in the rapidly evolving field of peptide conjugate therapeutics.

Comparison to Industry Standards

• The peptide conjugate drug class is extremely modular and flexible, making it applicable to a wide range of human disease states and medical indications.
• Peptide conjugates are emerging as a major therapeutic drug modality, with the potential to transform multiple therapeutic areas.
• This innovative class of drugs, exemplified by successful diabetes and weight loss treatments like Ozempic, Wegovy, Mounjaro and ZepBound, combines small a-helical peptides with functional moieties to enhance solubility and extend the duration of action.
• Decoy aims to build a robust portfolio of novel peptide conjugate therapeutics, initially focusing on infectious diseases and oncology, with the goal of becoming a fully integrated biopharmaceutical company at the forefront of this exciting field.

Related Party Transactions

• Dr. McVicar, a member of the Salarius board of directors, serves as a consultant to DeuteRx and is a consultant to an affiliate of DeuteRx.
• On January 12, 2022, Salarius entered into an acquisition and strategic collaboration agreement with DeuteRx, LLC, pursuant to which Salarius acquired targeted protein development portfolio.

Stakeholder Impact

• The merger is expected to benefit Salarius and Decoy stockholders by creating a company focused on innovative peptide conjugate therapeutics.
• The combined company's success will depend on its ability to develop and commercialize product candidates, which could impact patients with cancer and infectious diseases.
• The merger could result in changes to the combined company's board of directors and management, which may affect the business strategy and operations.

Next Steps

• Salarius intends to commence the Nasdaq initial listing process after the consummation of the Qualified Financing and the Merger Closing.
• Following the Merger Closing, Salarius has agreed to call a special stockholder meeting to approve, among other things, the conversion of the Series A Preferred Stock to be issued at the Merger Closing into shares of Salarius common stock.

Key Dates

Keywords

Merger, Decoy Therapeutics, Salarius Pharmaceuticals, Peptide conjugates, Oncology, Infectious diseases, SP-3164, P-PROTACs, Clinical trials, Financing